Request for Notification From Industry Organizations Interested in Participating in the Selection Process for a Nonvoting Industry Representative and Request for Nominations for a Nonvoting Industry Representative on an FDA Advisory Committee, 19101 [2011-8125]
Download as PDF
Federal Register / Vol. 76, No. 66 / Wednesday, April 6, 2011 / Notices
Act (21 U.S.C. 355, 360b, or 382), or
under section 351 of the Public Health
Service Act (42 U.S.C. 262), effective,
(see DATES) (see sections 306(c)(1)(B),
(c)(2)(A)(ii), and 201(dd) of the FD&C
Act (21 U.S.C. 335a(c)(1)(B), (c)(2)(A)(ii),
and 321(dd))). Any person with an
approved or pending drug product
application who knowingly employs or
retains as a consultant or contractor, or
otherwise uses the services of Dr.
Palazzo, in any capacity during Dr.
Palazzo’s debarment, will be subject to
civil money penalties (section 307(a)(6)
of the FD&C Act (21 U.S.C. 335b(a)(6))).
If Dr. Palazzo provides services in any
capacity to a person with an approved
or pending drug product application
during her period of debarment she will
be subject to civil money penalties
(section 307(a)(7) of the FD&C Act). In
addition, FDA will not accept or review
any abbreviated new drug applications
submitted by or with the assistance of
Dr. Palazzo during her period of
debarment (section 306(c)(1)(B) of the
FD&C Act.
Any application by Dr. Palazzo for
special termination of debarment under
section 306(d)(4) of the FD&C Act
should be identified with Docket No.
FDA–2010–N–0450 and sent to the
Division of Dockets Management (see
ADDRESSES). All such submissions are to
be filed in four copies. The public
availability of information in these
submissions is governed by 21 CFR
10.20(j).
Publicly available submissions may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: March 28, 2011.
Howard Sklamberg,
Director, Office of Enforcement, Office of
Regulatory Affairs.
[FR Doc. 2011–8152 Filed 4–5–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
mstockstill on DSKH9S0YB1PROD with NOTICES
[Docket No. FDA–2011–N–0002]
Request for Notification From Industry
Organizations Interested in
Participating in the Selection Process
for a Nonvoting Industry
Representative and Request for
Nominations for a Nonvoting Industry
Representative on an FDA Advisory
Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
VerDate Mar<15>2010
16:52 Apr 05, 2011
Jkt 223001
The Food and Drug
Administration (FDA) is requesting that
any industry organizations interested in
participating in the selection of a
nonvoting industry representative to
serve on its Allergenic Products
Advisory Committee notify FDA in
writing. A nominee may either be selfnominated or nominated by an
organization to serve as a nonvoting
industry representative. Nomination
will be accepted for current vacancies
effective with this notice.
DATES: Any industry organization
interested in participating in the
selection of an appropriate nonvoting
member to represent industry interests
must send a letter stating the interest to
FDA by May 6, 2011 for vacancies listed
in the notice. Concurrently, nomination
material for prospective candidates
should be sent to FDA by May 6, 2011.
ADDRESSES: All letters of interest and
nominations should be submitted in
writing to Gail Dapolito (see FOR
FURTHER INFORMATION CONTACT).
FOR FURTHER INFORMATION CONTACT: Gail
Dapolito, Center for Biologics
Evaluation and Research, Food and
Drug Administration, 1401 Rockville
Pike, Rockville, MD 20852–1448, 301–
827–1289, FAX: 301–827–0294, e-mail:
gail.dapolito@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
The Agency requests nominations for
a nonvoting industry representative on
the Allergenic Products Advisory
Committee. The Allergenic Products
Advisory Committee advises the
Commissioner or designee in
discharging responsibilities as they
relate to the regulation of allergenic
products. This Committee has nine
voting members. Members are asked to
provide their expert scientific and
technical advice to FDA to help make
sound decisions on the safety,
effectiveness, appropriate use, and
labeling of allergenic biological
products.
II. Selection Procedure
Any industry organization interested
in participating in the selection of an
appropriate nonvoting member to
represent industry interests should send
a letter stating that interest to the FDA
contact (see FOR FURTHER INFORMATION
CONTACT) within 30 days of publication
of this document. Within the
subsequent 30 days, FDA will send a
letter to each organization that has
expressed an interest, attaching a
complete list of all such organizations,
and a list of all nominees along with
their current resumes. The letter will
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
19101
also state that it is the responsibility of
the interested organizations to confer
with one another and to select a
candidate, within 60 days after the
receipt of the FDA letter, to serve as the
nonvoting member to represent industry
interests for the Allergenic Products
Advisory Committee.
The interested organizations are not
bound by the list of nominees in
selecting a candidate. However, if no
individual is selected within 60 days,
the Commissioner of Food and Drugs
will select the nonvoting member to
represent industry interests.
III. Application Procedure
Individuals may self-nominate and/or
an organization may nominate one or
more individuals to serve as a nonvoting
industry representative. A current
curriculum vitae and the name of the
committee of interest should be sent to
the FDA contact person within the 30
days following nomination. FDA will
forward all nominations to the
organizations expressing interest in
participating in the selection process for
the committee. (Persons who nominate
themselves as nonvoting industry
representatives will not participate in
the selection process).
FDA has a special interest in ensuring
that women, minority groups,
individuals with physical disabilities,
and small businesses are adequately
represented on its advisory committees
and, therefore, encourages nominations
for appropriately qualified candidates
from these groups. Specifically, in this
document, nominations for nonvoting
representatives of industry interests are
encouraged from the allergenic product
manufacturing industry.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: March 31, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–8125 Filed 4–5–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Advisory Council on Blood Stem Cell
Transplantation; Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
E:\FR\FM\06APN1.SGM
06APN1
Agencies
[Federal Register Volume 76, Number 66 (Wednesday, April 6, 2011)]
[Notices]
[Page 19101]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-8125]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0002]
Request for Notification From Industry Organizations Interested
in Participating in the Selection Process for a Nonvoting Industry
Representative and Request for Nominations for a Nonvoting Industry
Representative on an FDA Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting that any
industry organizations interested in participating in the selection of
a nonvoting industry representative to serve on its Allergenic Products
Advisory Committee notify FDA in writing. A nominee may either be self-
nominated or nominated by an organization to serve as a nonvoting
industry representative. Nomination will be accepted for current
vacancies effective with this notice.
DATES: Any industry organization interested in participating in the
selection of an appropriate nonvoting member to represent industry
interests must send a letter stating the interest to FDA by May 6, 2011
for vacancies listed in the notice. Concurrently, nomination material
for prospective candidates should be sent to FDA by May 6, 2011.
ADDRESSES: All letters of interest and nominations should be submitted
in writing to Gail Dapolito (see FOR FURTHER INFORMATION CONTACT).
FOR FURTHER INFORMATION CONTACT: Gail Dapolito, Center for Biologics
Evaluation and Research, Food and Drug Administration, 1401 Rockville
Pike, Rockville, MD 20852-1448, 301-827-1289, FAX: 301-827-0294, e-
mail: gail.dapolito@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
The Agency requests nominations for a nonvoting industry
representative on the Allergenic Products Advisory Committee. The
Allergenic Products Advisory Committee advises the Commissioner or
designee in discharging responsibilities as they relate to the
regulation of allergenic products. This Committee has nine voting
members. Members are asked to provide their expert scientific and
technical advice to FDA to help make sound decisions on the safety,
effectiveness, appropriate use, and labeling of allergenic biological
products.
II. Selection Procedure
Any industry organization interested in participating in the
selection of an appropriate nonvoting member to represent industry
interests should send a letter stating that interest to the FDA contact
(see FOR FURTHER INFORMATION CONTACT) within 30 days of publication of
this document. Within the subsequent 30 days, FDA will send a letter to
each organization that has expressed an interest, attaching a complete
list of all such organizations, and a list of all nominees along with
their current resumes. The letter will also state that it is the
responsibility of the interested organizations to confer with one
another and to select a candidate, within 60 days after the receipt of
the FDA letter, to serve as the nonvoting member to represent industry
interests for the Allergenic Products Advisory Committee.
The interested organizations are not bound by the list of nominees
in selecting a candidate. However, if no individual is selected within
60 days, the Commissioner of Food and Drugs will select the nonvoting
member to represent industry interests.
III. Application Procedure
Individuals may self-nominate and/or an organization may nominate
one or more individuals to serve as a nonvoting industry
representative. A current curriculum vitae and the name of the
committee of interest should be sent to the FDA contact person within
the 30 days following nomination. FDA will forward all nominations to
the organizations expressing interest in participating in the selection
process for the committee. (Persons who nominate themselves as
nonvoting industry representatives will not participate in the
selection process).
FDA has a special interest in ensuring that women, minority groups,
individuals with physical disabilities, and small businesses are
adequately represented on its advisory committees and, therefore,
encourages nominations for appropriately qualified candidates from
these groups. Specifically, in this document, nominations for nonvoting
representatives of industry interests are encouraged from the
allergenic product manufacturing industry.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: March 31, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-8125 Filed 4-5-11; 8:45 am]
BILLING CODE 4160-01-P